EMEA-000118-PIP03-15

Key facts

Invented name
Orencia
Active substance
Abatacept
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0005/2017
PIP number
EMEA-000118-PIP03-15
Pharmaceutical form(s)
  • Powder for concentrate for solution for infusion
  • Solution for injection
Condition(s) / indication(s)
Treatment of systemic lupus erythematosus
Route(s) of administration
  • Intravenous use
  • Subcutaneous use
Contact for public enquiries
Bristol-Myers Squibb Pharma EEIG
United Kingdom
Tel. +44 1895 52 3740
Fax +44 1895523677
E-mail: medical.information@bms.com

 

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating